Expertise in
5
conditions

Emmanuel Buc

Clermont-ferrand, FR 
Expertise in
5
conditions
Clermont-ferrand, FR 

Overview

Emmanuel Buc practices practicing medicine in Clermont-ferrand, France.

Mr. Buc is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Gastrointestinal Fistula, Colorectal Cancer, Liver Cancer, Pancreaticoduodenectomy, and Hepatectomy.

He is actively involved in clinical research, co-authoring 67 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Clermont-ferrand, France
Other Locations
CHU de Bordeaux
Pessac-sur-dordogne, France
CHU de Rouen
Rouen, France
Aubiere, France
Clichy-sous-bois, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Randomized Phase II Study Comparing 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI Followed by Two Months of Gemcitabine+Nab-paclitaxel, in Metastatic Pancreatic Cancer
Randomized Phase II Study Comparing 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI Followed by Two Months of Gemcitabine+Nab-paclitaxel, in Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: July 01, 2025
Intervention Type: Drug
Study Drugs: Irinotecan Liposomal Injection, 5-FU/LV, Nab-Paclitaxel, Gemcitabine
Study Phase: Phase 2
Randomised Phase II Study in Metastatic Pancreatic Cancer Evaluating FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem in First-line
Randomised Phase II Study in Metastatic Pancreatic Cancer Evaluating FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem in First-line
Enrollment Status: Completed
Publish Date: July 10, 2024
Intervention Type: Drug
Study Drugs: FOLFIRINOX, LV5FU2, FOLFIRI.3, Gemcitabine
Study Phase: Phase 2
View 1 Less Clinical Trial

67 Total Publications

Early Portomesenteric Thrombosis Following Pancreaticoduodenectomy: Risk Factors, Management and Outcomes.
Early Portomesenteric Thrombosis Following Pancreaticoduodenectomy: Risk Factors, Management and Outcomes.
Journal: Journal of surgical oncology
Published: March 28, 2026

Frequently Asked Questions about Emmanuel Buc

Is Emmanuel Buc a top-rated expert for Pancreaticoduodenectomy?

MediFind is an objective health platform that identifies experts based on real-world data. Emmanuel Buc is classified as an Advanced expert for Pancreaticoduodenectomy, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Emmanuel Buc participate in research or clinical trials?

Yes. Emmanuel Buc has published 67 articles and abstracts on conditions like Pancreaticoduodenectomy. You can view a list of Emmanuel Buc's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Buc's expertise for a condition
ConditionClose
      View All 13 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile